A compound of formula (I) or formula (Ia)
Wherein R
1
, R
a
, R
2
, X, R
3
, Y
1
, Y
2
, A, B and C are as defined herein. Also, pharmaceutical compositions comprising such compounds and excipients, methods of treating bacterial infections comprising administering such compounds, methods for making such compounds and hydrates of such compounds.
Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists
作者:Shan Jiang、Christos Iliopoulos-Tsoutsouvas、Fei Tong、Christina A. Brust、Catherine M. Keenan、Jimit Girish Raghav、Tian Hua、Simiao Wu、Jo-Hao Ho、Yiran Wu、Travis W. Grim、Nikolai Zvonok、Ganesh A. Thakur、Zhi-Jie Liu、Keith A. Sharkey、Laura M. Bohn、Spyros P. Nikas、Alexandros Makriyannis
DOI:10.1021/acs.jmedchem.0c02053
日期:2021.4.8
Thromboxane A2 receptor antagonists. III. Synthesis and pharmacological activity of 6,6-dimethylbicyclo(3.1.1.)heptane derivatives with a substituted sulfonylamino group at C-2.
作者:Kaoru SENO、Sanji HAGISHITA
DOI:10.1248/cpb.37.1524
日期:——
Four stereoisomers of the title compounds based on side chain ring junctions, (+)-7a, (+)-7b, (-)-7c and (-)-24, were synthesized from (-)-myrtenol and (+)-nopinone. The (1R,2R,3S,5S)-isomer (+)-7b had the most potent inhibitory activity against platelet aggregation and did not show partial agonist activity (shape change of platelets). We also synthesized the antipode, (-)-7b, and derivatives of (+)-7b